Skip to main content

MINI REVIEW article

Front. Endocrinol.
Sec. Thyroid Endocrinology
Volume 15 - 2024 | doi: 10.3389/fendo.2024.1433553
This article is part of the Research Topic Papillary Thyroid Cancer: Prognostic Factors and Risk Assessment View all 18 articles

Current status of the prediction for radio-iodine refractory thyroid cancer: a narrative review

Provisionally accepted
Yuhua Wang Yuhua Wang 1,2xiurong lu xiurong lu 3,4haiyan liu haiyan liu 1,5,6*
  • 1 Department of nuclear medicine, First Hospital of Shanxi Medical University, Taiyuan, Shaanxi, China
  • 2 Department of nuclear medicine, Shanxi Bethune Hospital, Shanxi Medical University, Taiyuan, Shanxi Province, China
  • 3 Department of Nuclear Medicine, First Hospital of Shanxi Medical University, Taiyuan, Shanxi Province, China
  • 4 Department of nuclear medicine, Linfen Central Hospital of Shanxi Province, linfen, China
  • 5 Shanxi Key Laboratory of Molecular Imaging, Shanxi Medical University, Taiyuan, Shanxi Province, China
  • 6 Collaborative Innovation Center for Molecular Imaging of Precision Medicine Shanxi Medical University, Taiyuan, China

The final, formatted version of the article will be published soon.

    It is well established that patients with the most differentiated thyroid cancers have a good prognosis, whereas when the disease develops into radio-iodine refractory thyroid cancer (RAIR) their prognosis is poor and the 10-year survival rate is low. At present, the therapeutic methods for RAIR are limited and have low efficacy. As a consequence, several models have been developed for predicting RAIR. The aim of this review was to describe recent developments regarding the factors that influence and predict the occurrence of RAIR. Many variables including demographic characteristics, tumor clinicopathology, serology changes, disease characteristics, and PET/CT results have been shown to be independent factors that influence the development of RAIR. The cut-off value derived from multivariate prediction models therefore effectively predicts the onset of RAIR. However, the current models for predicting RAIR were obtained through retrospective studies, and the prospective prediction studies are needed in the future to confirm their validity.

    Keywords: Radio-iodine refractory, Differentiated thyroid cancer, prediction, Radioactive iodine therapy, PET/CT

    Received: 16 May 2024; Accepted: 30 Sep 2024.

    Copyright: © 2024 Wang, lu and liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: haiyan liu, Department of nuclear medicine, First Hospital of Shanxi Medical University, Taiyuan, 030001, Shaanxi, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.